S&P 500   3,907.27 (-1.67%)
DOW   31,598.57 (-0.88%)
QQQ   284.01 (-3.23%)
AAPL   138.31 (-3.35%)
MSFT   255.77 (-1.87%)
FB   178.80 (-8.88%)
GOOGL   2,084.55 (-6.51%)
AMZN   2,063.96 (-4.05%)
TSLA   636.46 (-5.70%)
NVDA   160.82 (-4.83%)
BABA   83.04 (-4.80%)
NIO   14.80 (-7.50%)
AMD   90.83 (-4.46%)
CGC   4.84 (-6.74%)
MU   66.59 (-4.31%)
T   20.79 (+0.24%)
GE   72.38 (-4.08%)
F   12.32 (-3.98%)
DIS   100.62 (-4.92%)
AMC   10.62 (-8.29%)
PFE   52.79 (-0.17%)
PYPL   78.21 (-3.66%)
NFLX   178.85 (-4.58%)
S&P 500   3,907.27 (-1.67%)
DOW   31,598.57 (-0.88%)
QQQ   284.01 (-3.23%)
AAPL   138.31 (-3.35%)
MSFT   255.77 (-1.87%)
FB   178.80 (-8.88%)
GOOGL   2,084.55 (-6.51%)
AMZN   2,063.96 (-4.05%)
TSLA   636.46 (-5.70%)
NVDA   160.82 (-4.83%)
BABA   83.04 (-4.80%)
NIO   14.80 (-7.50%)
AMD   90.83 (-4.46%)
CGC   4.84 (-6.74%)
MU   66.59 (-4.31%)
T   20.79 (+0.24%)
GE   72.38 (-4.08%)
F   12.32 (-3.98%)
DIS   100.62 (-4.92%)
AMC   10.62 (-8.29%)
PFE   52.79 (-0.17%)
PYPL   78.21 (-3.66%)
NFLX   178.85 (-4.58%)
S&P 500   3,907.27 (-1.67%)
DOW   31,598.57 (-0.88%)
QQQ   284.01 (-3.23%)
AAPL   138.31 (-3.35%)
MSFT   255.77 (-1.87%)
FB   178.80 (-8.88%)
GOOGL   2,084.55 (-6.51%)
AMZN   2,063.96 (-4.05%)
TSLA   636.46 (-5.70%)
NVDA   160.82 (-4.83%)
BABA   83.04 (-4.80%)
NIO   14.80 (-7.50%)
AMD   90.83 (-4.46%)
CGC   4.84 (-6.74%)
MU   66.59 (-4.31%)
T   20.79 (+0.24%)
GE   72.38 (-4.08%)
F   12.32 (-3.98%)
DIS   100.62 (-4.92%)
AMC   10.62 (-8.29%)
PFE   52.79 (-0.17%)
PYPL   78.21 (-3.66%)
NFLX   178.85 (-4.58%)
S&P 500   3,907.27 (-1.67%)
DOW   31,598.57 (-0.88%)
QQQ   284.01 (-3.23%)
AAPL   138.31 (-3.35%)
MSFT   255.77 (-1.87%)
FB   178.80 (-8.88%)
GOOGL   2,084.55 (-6.51%)
AMZN   2,063.96 (-4.05%)
TSLA   636.46 (-5.70%)
NVDA   160.82 (-4.83%)
BABA   83.04 (-4.80%)
NIO   14.80 (-7.50%)
AMD   90.83 (-4.46%)
CGC   4.84 (-6.74%)
MU   66.59 (-4.31%)
T   20.79 (+0.24%)
GE   72.38 (-4.08%)
F   12.32 (-3.98%)
DIS   100.62 (-4.92%)
AMC   10.62 (-8.29%)
PFE   52.79 (-0.17%)
PYPL   78.21 (-3.66%)
NFLX   178.85 (-4.58%)
NASDAQ:APYX

Apyx Medical (APYX) Stock Forecast, Price & News

$3.29
-0.19 (-5.46%)
(As of 05/24/2022 11:29 AM ET)
Add
Compare
Today's Range
$3.28
▼
$3.54
50-Day Range
$3.11
▼
$7.91
52-Week Range
$3.01
▼
$17.50
Volume
973 shs
Average Volume
120,477 shs
Market Capitalization
$113.35 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.17
View Price History Chart DataSkip Price History Chart
30 days | 90 days | 365 days | Advanced Chart
Receive APYX News and Ratings via Email

Sign-up to receive the latest news and ratings for Apyx Medical and its competitors with MarketBeat's FREE daily newsletter.

Apyx Medical logo

About Apyx Medical

Apyx Medical Corporation, an energy technology company, develops, manufactures, and sells medical devices in the cosmetic and surgical markets worldwide. The company operates in two segments, Advanced Energy and Original Equipment Manufacturing (OEM). It offers Helium Plasma Generator for delivery of RF energy and helium to cut, coagulate and ablate soft tissue during open and laparoscopic surgical procedures. The company offers Renuvion branded products for the cosmetic surgery market that enable plastic surgeons, fascial plastic surgeons, and cosmetic physicians to provide controlled heat to the tissue to achieve their desired results; and J-Plasma branded products for the hospital surgical market. It also develops, manufactures, and sells disposable hand pieces, and OEM generators and accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.

Headlines

May 16, 2022 | finance.yahoo.com
Those who invested in Apyx Medical (NASDAQ:APYX) five years ago are up 70%
May 16, 2022 | americanbankingnews.com
Piper Sandler Cuts Apyx Medical (NASDAQ:APYX) Price Target to $6.00
May 15, 2022 | americanbankingnews.com
Zacks Investment Research Downgrades Apyx Medical (NASDAQ:APYX) to Sell
May 12, 2022 | seekingalpha.com
Apyx Medical Corporation (APYX) CEO Charles Goodwin on Q1 2022 Results - Earnings Call Transcript
May 12, 2022 | investing.com
Apyx Medical Corp. Misses Q1 EPS by 1c
May 12, 2022 | finance.yahoo.com
Apyx Medical Corporation Reports First Quarter 2022 Financial Results and Updates Full Year 2022 Financial Outlook
May 5, 2022 | nasdaq.com
Comparing Bitcoin Versus Apyx Medical Reveals New Low
April 4, 2022 | finance.yahoo.com
Apyx Medical Corporation to Release First Quarter of Fiscal Year 2022 Financial Results on May 12, 2022
April 4, 2022 | finance.yahoo.com
Apyx Medical Corporation Announces FDA 510(k) Submission with Clinical Study Support for the Use of the Renuvion® APR Handpiece for Aesthetic Procedures to Improve Appearance of Lax Skin
March 18, 2022 | benzinga.com
Apyx Medical's Return on Invested Capital Insights
March 18, 2022 | markets.businessinsider.com
APYX Sees 3-30% Revenue Growth, AVDL Awaits FDA Decision, KZR To Report MISSION Data In Q2...
March 17, 2022 | finance.yahoo.com
Apyx Medical Corporation Reports Fourth Quarter and Full Year 2021 Financial Results; Introduces Full Year 2022 Financial Outlook
March 16, 2022 | benzinga.com
Apyx Medical Earnings Preview
See More Headlines

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:APYX
Previous Symbol
CUSIP
N/A
CIK
719135
Web
www.apyxmedical.com
Phone
(727) 384-2323
Fax
800-323-1640
Employees
272
Year Founded
N/A

Sales & Book Value

Annual Sales
$48.52 million
Price / Sales
2.34
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.45 per share
Price / Book
2.27

Profitability

EPS (Most Recent Fiscal Year)
($0.47)
Net Income
$-15.17 million
Net Margins
-30.96%
Pretax Margin
-30.32%
Return on Equity
-30.00%
Return on Assets
-24.10%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
4.72
Quick Ratio
4.12

Price-To-Earnings

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A

Miscellaneous

Outstanding Shares
34,453,000
Free Float
31,008,000
Market Cap
$113.35 million
Optionable
Optionable

Company Calendar

Last Earnings
5/12/2022
Today
5/24/2022
Next Earnings (Estimated)
8/11/2022
Fiscal Year End
12/31/2022

MarketRank™

Overall MarketRank™

2.04 out of 5 stars

Medical Sector

542nd out of 1,423 stocks

Surgical & Medical Instruments Industry

62nd out of 138 stocks

Analyst Opinion: 3.5Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -













Apyx Medical (NASDAQ:APYX) Frequently Asked Questions

Is Apyx Medical a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Apyx Medical in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Apyx Medical stock.
View analyst ratings for Apyx Medical or view top-rated stocks.

Are investors shorting Apyx Medical?

Apyx Medical saw a increase in short interest in April. As of April 30th, there was short interest totaling 968,500 shares, an increase of 25.6% from the April 15th total of 771,100 shares. Based on an average daily trading volume, of 130,600 shares, the days-to-cover ratio is currently 7.4 days. Currently, 3.2% of the company's stock are sold short.
View Apyx Medical's Short Interest.

When is Apyx Medical's next earnings date?

Apyx Medical is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022.
View our earnings forecast for Apyx Medical.

How were Apyx Medical's earnings last quarter?

Apyx Medical Co. (NASDAQ:APYX) announced its quarterly earnings results on Thursday, May, 12th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.15) by $0.02. Apyx Medical had a negative net margin of 30.96% and a negative trailing twelve-month return on equity of 30.00%. During the same period in the prior year, the business earned ($0.14) EPS.
View Apyx Medical's earnings history.

What guidance has Apyx Medical issued on next quarter's earnings?

Apyx Medical issued an update on its FY 2022 earnings guidance on Thursday, May, 19th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $52.50 million-$59.00 million, compared to the consensus revenue estimate of $55.07 million.

What price target have analysts set for APYX?

4 analysts have issued 12 month target prices for Apyx Medical's stock. Their forecasts range from $6.00 to $17.00. On average, they anticipate Apyx Medical's share price to reach $12.25 in the next year. This suggests a possible upside of 273.5% from the stock's current price.
View analysts' price targets for Apyx Medical or view top-rated stocks among Wall Street analysts.

Who are Apyx Medical's key executives?
Apyx Medical's management team includes the following people:
  • Mr. Charles D. Goodwin II, Pres, CEO & Director (Age 56, Pay $892.97k)
  • Ms. Tara H. Semb, CFO, Treasurer & Sec. (Age 52, Pay $531.67k)
  • Mr. Moshe Citronowicz, Sr. VP (Age 69, Pay $432.49k)
  • Mr. Todd Hornsby, Exec. VP (Age 46, Pay $590.66k)
What other stocks do shareholders of Apyx Medical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Apyx Medical investors own include Main Street Capital (MAIN), Johnson & Johnson (JNJ), ONEOK (OKE), Occidental Petroleum (OXY), Procter & Gamble (PG), STORE Capital (STOR), Wells Fargo & Company (WFC), Boeing (BA), Bank of America (BAC) and Delta Air Lines (DAL).

What is Apyx Medical's stock symbol?

Apyx Medical trades on the NASDAQ under the ticker symbol "APYX."

Who are Apyx Medical's major shareholders?

Apyx Medical's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Archon Capital Management LLC (6.78%), BlackRock Inc. (5.73%), Vanguard Group Inc. (4.54%), State Street Corp (1.62%), Renaissance Technologies LLC (1.49%) and Royce & Associates LP (1.34%).
View institutional ownership trends for Apyx Medical.

Which institutional investors are selling Apyx Medical stock?

APYX stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Goldman Sachs Group Inc., White Pine Capital LLC, JPMorgan Chase & Co., Millrace Asset Group Inc., BlackRock Inc., Northern Trust Corp, and Vanguard Group Inc..
View insider buying and selling activity for Apyx Medical or view top insider-selling stocks.

Which institutional investors are buying Apyx Medical stock?

APYX stock was bought by a variety of institutional investors in the last quarter, including Archon Capital Management LLC, Banco Santander S.A., Greenwood Capital Associates LLC, Invenire Partners LP, Signaturefd LLC, Renaissance Technologies LLC, Walleye Capital LLC, and State Street Corp.
View insider buying and selling activity for Apyx Medical or or view top insider-buying stocks.

How do I buy shares of Apyx Medical?

Shares of APYX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Apyx Medical's stock price today?

One share of APYX stock can currently be purchased for approximately $3.28.

How much money does Apyx Medical make?

Apyx Medical has a market capitalization of $113.01 million and generates $48.52 million in revenue each year. The company earns $-15.17 million in net income (profit) each year or ($0.47) on an earnings per share basis.

How many employees does Apyx Medical have?

Apyx Medical employs 272 workers across the globe.

What is Apyx Medical's official website?

The official website for Apyx Medical is www.apyxmedical.com.

How can I contact Apyx Medical?

Apyx Medical's mailing address is 5115 Ulmerton Road, Clearwater FL, 33760. The company can be reached via phone at (727) 384-2323, via email at [email protected], or via fax at 800-323-1640.

This page was last updated on 5/24/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits Financial Juice YouTube

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.